This week we report an exceptional increase in U.S. Biotech venture capital funding. Compared to the 1st quarter of last year, accumulated biotech venture capital funding in the United States has increased by staggering 106%, reaching USD 8,953m so far (USD 4,349m in Q1 2020).
The analysis of deal count and funding volume by ticket size reveals the main driver of the significant growth: The number of deals with a ticket size greater than USD 25m nearly doubled while the funding volume increased from USD 3,499m to USD 8,393m (+140%).
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: